August User Fee Calendar Features Gene Therapy, Analgesics, And Of Course Oncology
Executive Summary
Sixteen applications are in line for US FDA decisions in August. Ten are novel agents.
You may also be interested in...
BioMarin All Set For Hemophilia Gene Therapy Approval, But Is It Overestimating Demand?
Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.
Gilead To File Filgotinib For RA in 2019, Earlier Than Forecast
Concerns the Galapagos-partnered JAK inhibitor would be held back by a testicular toxicity study have been calmed by positive FDA talks and a submission is due before the end of the year.
Breaking Up With Breakthrough: Trevena And Tonix Lose Designation, But Continue With Pivotal Plans
US FDA rescinds breakthrough designations for Tonix’ PTSD therapy Tonyma and Trevena’s novel pain drug Olinvo after clinical trial disappointments – and after identifying other regulatory pathways to market.